NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

Core Insights - NeuroOne Medical Technologies Corporation has appointed Emily Johns as General Counsel and Corporate Secretary, enhancing its management team [1][2] - The appointment is expected to reduce overall legal costs and support the company's strategic growth initiatives [2] Management Team Enhancement - Emily Johns brings nearly a decade of experience working with NeuroOne and has a strong background in legal matters related to biotechnology companies [2] - Her previous role as a partner at Honigman LLP involved representing NeuroOne in transactional work since 2017 [2] - The company believes her legal expertise will be invaluable as it scales its operations [2] Stock Options and Compensation - In connection with her appointment, Ms. Johns received an option to purchase 500,000 shares of the company's common stock at an exercise price of $0.611 per share [3] - The new senior director of quality assurance and regulatory affairs was also granted an option to purchase 75,000 shares under similar terms [3] Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for neurological disorders, including epilepsy and Parkinson's disease [4] - The company aims to improve patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and chronic pain [4]